The Cooper Companies, Inc. $COO Stock Bought by New York Life Investment Management LLC

New York Life Investment Management LLC grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 204.0% during the third quarter, Holdings Channel.com reports. The firm owned 81,502 shares of the medical device company’s stock after acquiring an additional 54,688 shares during the quarter. New York Life Investment Management LLC’s holdings in Cooper Companies were worth $4,607,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Essential Partners LLC lifted its position in shares of Cooper Companies by 23.4% in the first quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock worth $62,000 after purchasing an additional 166 shares in the last quarter. Candriam S.C.A. grew its position in Cooper Companies by 2.8% in the third quarter. Candriam S.C.A. now owns 8,162 shares of the medical device company’s stock valued at $461,000 after purchasing an additional 220 shares in the last quarter. Basecamp Wealth Advisors LLC grew its position in Cooper Companies by 20.8% in the first quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company’s stock valued at $111,000 after purchasing an additional 268 shares in the last quarter. Avalon Trust Co bought a new position in Cooper Companies in the second quarter valued at $25,000. Finally, Elevation Wealth Partners LLC increased its stake in Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. cut their price target on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Zacks Research cut Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th. Robert W. Baird set a $61.00 price objective on Cooper Companies and gave the company a “neutral” rating in a report on Thursday, September 10th. Bank of America downgraded Cooper Companies from a “buy” rating to a “neutral” rating and lowered their target price for the company from $80.00 to $65.00 in a research report on Thursday, September 10th. Finally, UBS Group dropped their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $68.60.

Read Our Latest Stock Report on Cooper Companies

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Paul A. Keel acquired 4,701 shares of the business’s stock in a transaction on Friday, September 11th. The stock was purchased at an average price of $53.18 per share, with a total value of $249,999.18. Following the acquisition, the director directly owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $54.11 per share, for a total transaction of $378,770.00. Following the transaction, the director owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 34,701 shares of company stock worth $1,880,039. Corporate insiders own 2.08% of the company’s stock.

Cooper Companies Stock Performance

COO opened at $62.65 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The business has a fifty day simple moving average of $58.49 and a 200 day simple moving average of $68.15. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The company has a market capitalization of $11.91 billion, a PE ratio of 21.38, a price-to-earnings-growth ratio of 2.46 and a beta of 0.83.

Cooper Companies (NASDAQ:COO – Get Free Report) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the business earned $0.49 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Research analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 9th that authorizes the company to repurchase $3 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its shares through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Key Stories Impacting Cooper Companies

Investors following COO have been watching these stories:

  • Positive Sentiment: A recent article highlights Cooper’s relatively high cash yield, suggesting investors may be overlooking a potential source of value. The supplied information does not include the article’s supporting figures or analysis. Why Is Everyone Ignoring Cooper Companies Stock’s High Cash Yield?
  • Negative Sentiment: Rosen Law Firm says it is investigating potential securities claims tied to allegations that Cooper may have provided materially misleading business information. The notices encourage affected investors to contact the firm; they do not establish wrongdoing or indicate that a claim has been proven. The investigation could nevertheless weigh on sentiment and raise concerns about potential legal costs or reputational impact. Rosen investigation notice Rosen investor notice

Cooper Companies Company Profile

(Free Report)

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.

Featured Stories

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).

Institutional Ownership by Quarter for Cooper Companies (NASDAQ:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.